
AI AnalysisReported
Lilly and Novo Nordisk turn to amylin drugs for next wave of obesity treatments
Both drugmakers are developing amylin-based therapies as a new biological approach to treating obesity and diabetes beyond GLP-1 drugs.
By EGazette AI · · 1 min read